MetaVia says DA-1726 obesity Phase 1 Part 3 patients reach 48 mg and 64 mg target doses

MetaVia Inc.

MetaVia Inc.

MTVA

0.00
  • Metavia completed dose titration in Phase 1 Part 3 testing obesity drug candidate DA-1726, with all active patients reaching 48 mg or 64 mg.
  • The trial is evaluating one-step titration to 48 mg or two-step titration to 64 mg to improve tolerability at higher doses.
  • Topline data remains scheduled for the fourth quarter of 2026.
  • Earlier Phase 1 MAD results cited 9.1% mean weight loss at 48 mg over 8 weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082116), on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.